Fig. 3 | Scientific Reports

Fig. 3

From: Changes in methylation associated with development of metabolic syndrome in testicular cancer patients treated with cisplatin chemotherapy

Fig. 3

(A) Methylation of AC090023 in TC patients with or without MetS before the start of CBCT. (B) Changes in methylation of AC090023, NCAM2 and TOM1L2 one year after CBCT in TC patients with or without MetS before start of CBCT. (C) Changes in global methylation (LINE-1) and methylation of TOM1L2 one year after CBCT in TC patients who had MetS prior to CBCT, developed MetS within five years, or never developed MetS. * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001. CBCT = cisplatin-based chemotherapy; MetS = metabolic syndrome; TC = testicular cancer.

Back to article page